Cargando…

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer

Bulk chemotherapy and drug release strategies for cancer treatment have been associated with lack of specificity and high drug concentrations that often result in toxic side effects. This work presents the results of an experimental study of cancer drugs (prodigiosin or paclitaxel) conjugated to Lut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obayemi, J. D., Salifu, A. A., Eluu, S. C., Uzonwanne, V. O., Jusu, S. M., Nwazojie, C. C., Onyekanne, C. E., Ojelabi, O., Payne, L., Moore, C. M., King, J. A., Soboyejo, W. O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237454/ https://www.ncbi.nlm.nih.gov/pubmed/32427904 http://dx.doi.org/10.1038/s41598-020-64979-1

Ejemplares similares

Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer
por: Jusu, S. M., et al.
Publicado: (2020)

Targeted drug-loaded PLGA-PCL microspheres for specific and localized treatment of triple negative breast cancer
por: Nwazojie, Chukwudalu C., et al.
Publicado: (2023)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Anomalous Release Kinetics of Prodigiosin from Poly-N-Isopropyl-Acrylamid based Hydrogels for The Treatment of Triple Negative Breast Cancer
por: Danyuo, Y., et al.
Publicado: (2019)

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
por: Roy, Jyoti, et al.
Publicado: (2019)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.
por: Corbin, A.
Publicado: (1982)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells
por: Liu, Lanxia, et al.
Publicado: (2014)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
por: Fodor, Klara, et al.
Publicado: (2020)

Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide
por: Couty, Mickael, et al.
Publicado: (2021)

Targeted Imaging Agent to HSP70 Induced In Vivo
por: Ghosh, Pradip, et al.
Publicado: (2020)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Squamous cell carcinoma of the prostate following treatment with an LHRH–agonist: a rare case of transformation of adenocarcinoma of the prostate
por: Al–Qassim, Zubair, et al.
Publicado: (2014)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
por: Rutqvist, L. E., et al.
Publicado: (1992)

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells
por: Li, Xiaoyong, et al.
Publicado: (2016)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study
por: Morote, Juan, et al.
Publicado: (2022)

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2021)

Triple-target stimuli-responsive anti-COVID-19 face mask with physiological virus-inactivating agents
por: Müller, Werner E. G., et al.
Publicado: (2021)

Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment
por: Battogtokh, Gantumur, et al.
Publicado: (2018)

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Targeting CD56 with an antibody–drug conjugate in Merkel cell carcinoma
por: Leiendecker, L., et al.
Publicado: (2021)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aimhp4fvgqrtlshntf0jl1tne1